Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile

Maria Giovanna Lupo; Diletta Arcidiacono; Alice Zaramella; Fabio Fimiani; Paolo Calabrò; Angelo Baldassare Cefalù; Maurizio Averna; Laura D'Erasmo; Marcello Arca; Sara De Martin; Alberto Zambon; Nicola Ferri

doi:10.1016/j.athplu.2021.05.001

Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile

Maria Giovanna Lupo, Diletta Arcidiacono, Alice Zaramella, Fabio Fimiani, Paolo Calabrò, Angelo Baldassare Cefalù, Maurizio Averna, Laura D'Erasmo, Marcello Arca, Sara De Martin, Alberto Zambon, Nicola Ferri

Research output: Contribution to journal › Article › peer-review

Abstract

Lomitapide, a drug for the treatment of homozygous familial hypercholesterolemia patients, reduced total and LDL cholesterol but no significant changes were observed on PCSK9 and Lp(a) plasma levels. Some changes of inflammatory mediators were also observed, including hsCRP, which may suggest an anti-inflammatory effect.

Original language	English
Pages (from-to)	7-9
Journal	Atherosclerosis Plus
Volume	43
DOIs	https://doi.org/10.1016/j.athplu.2021.05.001
Publication status	Published - Sept 2021

Keywords

Familial hypercholesterolemia
Lomitapide
lp(a)
pcsk9

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Internal Medicine

Access to Document

10.1016/j.athplu.2021.05.001

Cite this

Lupo, M. G., Arcidiacono, D., Zaramella, A., Fimiani, F., Calabrò, P., Cefalù, A. B., Averna, M., D'Erasmo, L., Arca, M., De Martin, S., Zambon, A., & Ferri, N. (2021). Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile. Atherosclerosis Plus, 43, 7-9. https://doi.org/10.1016/j.athplu.2021.05.001

Lupo, MG, Arcidiacono, D , Zaramella, A, Fimiani, F, Calabrò, P, Cefalù, AB, Averna, M, D'Erasmo, L, Arca, M, De Martin, S, Zambon, A & Ferri, N 2021, 'Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile', Atherosclerosis Plus, vol. 43, pp. 7-9. https://doi.org/10.1016/j.athplu.2021.05.001

@article{c5e7e17cfbba4e9ca9fe2b03d08c3e7c,

title = "Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile",

abstract = "Lomitapide, a drug for the treatment of homozygous familial hypercholesterolemia patients, reduced total and LDL cholesterol but no significant changes were observed on PCSK9 and Lp(a) plasma levels. Some changes of inflammatory mediators were also observed, including hsCRP, which may suggest an anti-inflammatory effect.",

keywords = "Familial hypercholesterolemia, Lomitapide, lp(a), pcsk9",

author = "Lupo, {Maria Giovanna} and Diletta Arcidiacono and Alice Zaramella and Fabio Fimiani and Paolo Calabr{\`o} and Cefal{\`u}, {Angelo Baldassare} and Maurizio Averna and Laura D'Erasmo and Marcello Arca and {De Martin}, Sara and Alberto Zambon and Nicola Ferri",

note = "Publisher Copyright: {\textcopyright} 2021 The Author(s)",

year = "2021",

month = sep,

doi = "10.1016/j.athplu.2021.05.001",

language = "English",

volume = "43",

pages = "7--9",

journal = "Atherosclerosis Plus",

issn = "2667-0909",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile

AU - Lupo, Maria Giovanna

AU - Arcidiacono, Diletta

AU - Zaramella, Alice

AU - Fimiani, Fabio

AU - Calabrò, Paolo

AU - Cefalù, Angelo Baldassare

AU - Averna, Maurizio

AU - D'Erasmo, Laura

AU - Arca, Marcello

AU - De Martin, Sara

AU - Zambon, Alberto

AU - Ferri, Nicola

PY - 2021/9

Y1 - 2021/9

N2 - Lomitapide, a drug for the treatment of homozygous familial hypercholesterolemia patients, reduced total and LDL cholesterol but no significant changes were observed on PCSK9 and Lp(a) plasma levels. Some changes of inflammatory mediators were also observed, including hsCRP, which may suggest an anti-inflammatory effect.

AB - Lomitapide, a drug for the treatment of homozygous familial hypercholesterolemia patients, reduced total and LDL cholesterol but no significant changes were observed on PCSK9 and Lp(a) plasma levels. Some changes of inflammatory mediators were also observed, including hsCRP, which may suggest an anti-inflammatory effect.

KW - Familial hypercholesterolemia

KW - Lomitapide

KW - lp(a)

KW - pcsk9

UR - http://www.scopus.com/inward/record.url?scp=85109433692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85109433692&partnerID=8YFLogxK

U2 - 10.1016/j.athplu.2021.05.001

DO - 10.1016/j.athplu.2021.05.001

M3 - Article

AN - SCOPUS:85109433692

SN - 2667-0909

VL - 43

SP - 7

EP - 9

JO - Atherosclerosis Plus

JF - Atherosclerosis Plus

ER -

Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this